Cell compositions derived from dedifferentiated reprogrammed cells

• US 9,109,245 B2
• Filed: 02/06/2013
• Issued: 08/18/2015
• Est. Priority Date: 04/22/2009
• Status: Active Grant

• Current Assignee: Viacyte Incorporated (Vertex Pharmaceuticals Incorporated)
• Original Assignee: Viacyte Incorporated (Vertex Pharmaceuticals Incorporated)
• Inventors: Agulnick, Alan D., Kelly, Olivia, Ohi, Yuki, Robins, Allan, Schultz, Thomas
• Primary Examiner(s): Driscoll, Lora E Barnhart
• Application Number:
  US13/761,078
• Publication Number:
  US 20130164787A1
• Time in Patent Office: 923 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 35/39 Pancreas; Islets of Langerhans Langerhans cells of epidermis A61K35/36
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/117 Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
• CPC Class Codes: C12N 2501/16 Activin; Inhibin; Mullerian inhibiting substance
• CPC Class Codes: C12N 2501/195 Heregulin, neu differentiation factor
• CPC Class Codes: C12N 2501/385 of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
• CPC Class Codes: C12N 2501/41 Hedgehog proteins; Cyclopamine (inhibitor)
• CPC Class Codes: C12N 2501/415 Wnt; Frizzeled
• CPC Class Codes: C12N 2501/727 Kinases (EC 2.7.)
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2506/45 from artificially induced pluripotent stem cells
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.

Claims

1. An in vitro human pancreatic endoderm cell population in a media comprising an ERBB receptor tyrosine kinase activating agent.

2. The pancreatic endoderm cell population of claim 1, wherein the ERRB receptor tyrosine kinase activating agent comprises an epidermal growth factor (EGF) family ligand.

3. The pancreatic endoderm cell population of claim 2, wherein the EGF family ligand is selected from the group consisting of Heregulin-1 (Neuregulin-1), Heregulin-2 (Neuregulin-2), Heregulin-3 (Neuregulin-3) and Heregulin-4 (Neuregulin-4).

4. The pancreatic endoderm cell population of claim 3, wherein the EGF family ligand comprises heregulin-1 and heregulin-4.

5. The pancreatic endoderm cell population of claim 3, wherein the EGF family ligand comprises Heregulin-4 (Neuregulin-4).

6. The pancreatic endoderm population of claim 3 wherein the EGF family ligand is Heregulin-1 (Neuregulin-1).

7. The pancreatic endoderm population of claim 6 wherein Heregulin-1 (Neuregulin-1) is heregulin-1β

.

8. The pancreatic endoderm population of claim 7 wherein the heregulin-1β

is a fragment of the natural protein.